SPHDF OTC
Santhera Pharmaceuticals Holding AG
1W: -7.5%
1M: -21.3%
3M: -21.3%
YTD: +37.1%
1Y: +37.4%
3Y: +2591.2%
5Y: +115722.8%
$18.30
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$39M
-62.2% ▼
5Y CAGR: -12.3%
Gross Profit
$23M
-77.1% ▼
5Y CAGR: -20.0%
Operating Income
-$33M
-148.5% ▼
Net Income
-$42M
-176.6% ▼
EPS (Diluted)
$-3.69
-173.7% ▼
EBITDA
-$16M
-120.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $15M | -$2M | $7M | $103M | $39M |
| YoY Growth | -80.1% | -110.6% | +568.5% | +1283.8% | -62.2% |
| Cost of Revenue | $10M | $4M | $4M | $3M | $16M |
| Gross Profit | $5M | -$5M | $4M | $100M | $23M |
| Gross Margin | 30.5% | 336.2% | 51.9% | 96.9% | 58.7% |
| R&D Expenses | $34M | $30M | $31M | $19M | $26M |
| SG&A Expenses | $24M | $22M | $25M | $31M | $30M |
| Operating Expenses | $58M | $52M | $56M | $31M | $57M |
| Operating Income | -$53M | -$57M | -$52M | $69M | -$33M |
| Operating Margin | -353.7% | 3566.6% | -695.5% | 66.6% | -85.3% |
| Interest Expense | $7M | $16M | $20M | $21M | $20M |
| Income Before Tax | -$67M | -$55M | -$71M | $55M | -$42M |
| Tax Expense | $203K | $809K | $460K | $38K | $312K |
| Net Income | -$68M | -$56M | -$71M | $55M | -$42M |
| Net Margin | -450.8% | 3481.3% | -951.1% | 53.0% | -107.3% |
| EPS (Diluted) | $-50.81 | $-16.25 | $-11.67 | $5.01 | $-3.69 |
| EBITDA | -$53M | -$35M | -$47M | $79M | -$16M |
| Shares Outstanding | 1M | 3M | 6M | 11M | 11M |